After the stupendous success of Celator Pharma $CPXX, there has been a lot of interest in small biotech working in the hematology space. One worry for that approach would have been: does success come to the same space twice? But the good thing is that, CPXX was concentrated on a very small section of AML - secondary AML where patients are fit to do chemotherapy.

The other population - secondary AML patients who are too sick for chemotherapy - is the other important space made interesting by CPXX. And in this space, by virtue of the following single slide, MEI Pharma or $MEIP turns out to be the most interesting player:

*** L2 or above subscription required to read the rest of the article ... Login or Subscribe/Upgrade here